Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
Recruiting
Phase 4
Interventional Study
Type 2 Diabetes Mellitus
Hypercholesterolemia / Elevated LDL Cholesterol
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 35 – 60
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 126 (estimated)
- Sponsor
- Bahria University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This Open-label, randomized clinical trial evaluates the comparative efficacy and safety of dual versus triple lipid-lowering therapy using rosuvastatin, ezetimibe, and bempedoic acid in patients with type 2 diabetes mellitus and elevated LDL cholesterol. The study aims to determine whether adding bempedoic acid to standard dual therapy provides superior lipid control without compromising safety. …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Males and females
* Age 35-60 years
* HbA1c ≥ 7.0 (≥ 48 mmol/mol)
* On stable anti-diabetic therapy for at least 3 months
* LDL-C \> 100 mg/dL on at least two occasions
* Diagnosed with hypercholesterolemia
* Establish high cardiovascular risk (e.g, previous MI, stroke or athe…
Contacts